---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-049085"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2024-04-26T23:59:59+00:00"
generated_at: "2026-06-03T06:11:15.944088+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics appoints Sung H. Lee as EVP, CFO effective May 8, 2024

## Summary
- Annual base salary of $550,000; target bonus 45% of base under corporate bonus plan.
- Signing bonus of $80,000; repayable if voluntarily resigns or terminated for cause within 12 months.
- Initial equity awards: $1,682,500 RSU, $1,682,500 stock options (Black-Scholes), $1,670,000 performance-based PSU.
- Lee replaces CEO Robert I. Blum, who had been serving as interim principal financial officer.
- Prior roles include CFO at Vir Biotechnology, MorphoSys AG, and Sangamo Therapeutics.

## SEC filing metadata
- accession: 0000950170-24-049085
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2024-04-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017024049085/0000950170-24-049085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017024049085/cytk-20240423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-049085
- JSON: https://secwatch.observer/filing/0000950170-24-049085.json
- Plain text: https://secwatch.observer/filing/0000950170-24-049085.txt

## Key facts
- Executive change
  Sung H. Lee was appointed as Executive Vice President, Chief Financial Officer at CYTOKINETICS INC.
  - Action: appointed
  - Role: Executive Vice President, Chief Financial Officer
  source text: On April 23, 2024, Cytokinetics, Incorporated (the “Company”) entered into an employment offer letter (the “Offer Letter”) with Sung H. Lee, pursuant to which Mr. Lee has agreed to serve as the Company’s Executive Vice President (“EVP”), Chief Financial Officer, effective as of May 8, 2024 (the “Start Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000095017024049085/0000950170-24-049085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.